| 1 |
Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
|
| 2 |
ClinicalTrials.gov (NCT02421588) Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients. U.S. National Institutes of Health.
|
| 3 |
Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
|
| 4 |
ClinicalTrials.gov (NCT02611024) Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
|
| 5 |
ClinicalTrials.gov (NCT05072106) Study to Evaluate the Effect of Bosentan on the Pharmacokinetics of Lurbinectedin in Patients With Advanced Solid Tumors
|
| 6 |
ClinicalTrials.gov (NCT02210364) Study of Lurbinectedin (PM01183) in Combination With Capecitabine in Patients With Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic Colorectal Cancer (CRC).
|
| 7 |
ClinicalTrials.gov (NCT01951157) A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients
|
| 8 |
ClinicalTrials.gov (NCT02448537) A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas
|
| 9 |
ClinicalTrials.gov (NCT06203210) A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
|
| 10 |
ClinicalTrials.gov (NCT05740566) Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
|
|
|
|
|
|
|
